Ezra vs. Prenuvo vs. YEARS: A Full-Body Scan Comparison

The market for preventive full-body screenings is expanding rapidly. Driven by a new wave of health consciousness and the desire to proactively address disease, more people are seeking comprehensive insights into their bodies. Providers like Ezra and Prenuvo dominate the conversation in the US with their MRI-based scans. But a look beneath the surface reveals a crucial truth: a sharp image alone is only a small part of modern preventive medicine.

This article provides a deep, evidence-based comparison of Ezra, Prenuvo, and the Berlin-based longevity clinic, YEARS. We compare not just the technologies, but the medical philosophies behind them. Anyone considering a comprehensive health diagnostic should understand the difference between an isolated picture and an integrated medical dossier built from function, genetics, and research.

At a Glance: How Do Ezra, Prenuvo, and YEARS Compare?

At first glance, all three companies offer "full-body screenings." The fundamental differences lie in their medical approach and diagnostic depth. Each represents a distinct philosophy of prevention.

• Ezra is a US-based provider focused on fast, AI-powered full-body MRI scans. A scan often takes only 30 to 60 minutes. Ezra positions itself as an accessible entry point into imaging-based preventive care.
• Prenuvo, also from the US, is considered a premium provider of imaging. Its scans are longer and use specialized MRI protocols to achieve high image quality. The clear focus is on providing the best possible structural depiction of the body.
• YEARS is a physician-led longevity clinic in Berlin with a fundamentally different approach. Here, a full-body MRI is just one component of a comprehensive diagnostic system. YEARS integrates deep lab diagnostics with up to 230+ biomarkers, functional testing, genomics, and a "Clinic-as-a-Study" model with its own biobank.

The critical distinction is not whether an MRI is performed, but how the results are interpreted and placed within a larger medical context: a snapshot of the body versus a complete medical dossier.

MRI Technology Deep Dive: 3T vs. 1.5T, Scan Times, and Protocols

The debate over the magnetic field strength of MRI scanners—3 Tesla (3T) at Ezra versus 1.5 Tesla (1.5T) at Prenuvo—is technical but relevant to diagnostic quality.

A 3T MRI theoretically offers a higher signal-to-noise ratio, which can lead to sharper images or shorter scan times. Ezra leverages this for efficient, rapid protocols. The downside can be more image artifacts, which require experienced radiological interpretation.

A 1.5T MRI, as used by Prenuvo, is considered a robust and proven standard. With optimized, multiparametric protocols, it can achieve excellent image quality with high diagnostic confidence. Studies show that for many screening applications, an optimized 1.5T protocol can have at least equivalent, and sometimes superior, diagnostic specificity compared to a fast 3T scan (Müller et al., Radiology Today, 2022).

YEARS integrates a full-body MRI as part of the YEARS Evolve® program, based on a proprietary sequence. The clinical relevance of the imaging is paramount, not the scan speed. However, another point is more decisive: YEARS acknowledges the systemic limitations of MRI imaging alone. For lung function, for example, an MRI has limited diagnostic value. That's why YEARS also performs body plethysmography, a comprehensive lung function test that goes far beyond simple spirometry, providing detailed information on lung volume, gas exchange, and exercise capacity.

Without functional data, the picture remains incomplete. This is true for any imaging, regardless of the provider.

The Invisible Foundation: Why 230+ Biomarkers Matter More Than an MRI Alone

This is where the major weakness of imaging-only providers lies. An MRI shows structural anomalies—a tumor, a cyst, an aneurysm. What it doesn't show are the functional and metabolic imbalances that often precede these problems by years.

Even the YEARS Core® program analyzes 87+ biomarkers that go far beyond a standard check-up:

• ApoB (Apolipoprotein B): Conventional tests measure LDL cholesterol. ApoB measures the exact number of atherogenic particles that cause arterial plaque. Numerous studies confirm that ApoB is the more precise predictor of cardiovascular risk (Walldius & Jungner, The Lancet, 2006).
• HOMA-IR Index: This value measures insulin resistance, an early warning sign for type 2 diabetes that can become apparent years before fasting blood sugar rises.
• hs-CRP (high-sensitivity C-reactive protein): A marker for silent, chronic inflammation, a central driver of cardiovascular disease, neurodegenerative disorders, and cancer. In the JUPITER study, patients with elevated hs-CRP but normal LDL benefited significantly from prophylactic statin therapy (Ridker et al., NEJM, 2008).
• NT-proBNP: A sensitive marker for cardiac muscle strain that can indicate the early stages of heart failure.

These markers are standard in the Core® program. Providers like Ezra and Prenuvo do not capture this dimension of health. A patient could receive a structurally normal scan while their blood values already indicate an elevated risk of a heart attack within the next ten years.

The YEARS Evolve® (120+ biomarkers) and YEARS Ultimate® (230+ biomarkers) programs go even deeper: hormones like testosterone, DHEA-S, and cortisol, oxidized LDL, the Omega-3 Index, amino acids, and cytokine profiles combine to create a multidimensional view of health that no MRI scan can provide.

Early Cancer Detection: Liquid Biopsy as a Smart MRI Complement

Many patients hope a full-body MRI will provide effective early cancer detection. The numbers are sobering: non-specific full-body MRIs detect a malignant tumor in only about 1–2% of asymptomatic individuals (Schmidt et al., JAMA Oncology, 2023).

A more promising approach involves Multi-Cancer Early Detection (MCED) tests, also known as liquid biopsies. These blood tests analyze circulating tumor DNA (ctDNA) to detect cancer cells at a very early stage.

Starting with the Evolve® program, YEARS integrates a liquid biopsy (truCheck) that can screen for over 70 different solid tumor types. In a prospective study with over 10,000 participants, the test detected cancer with high accuracy, often before symptoms appeared (Parikh et al., Annals of Oncology, 2021).

The combination of structural imaging and molecular diagnostics creates a far more powerful approach to early cancer detection than imaging alone. Here, too, imaging-only providers hit their limits.

Biological Age: Are We Measuring What Truly Matters for Longevity?

Chronological age and biological age can be far apart. Modern longevity research uses epigenetic clocks to determine the functional state of cells and organ systems. These clocks analyze DNA methylation patterns, which change throughout life and correlate strongly with health risks and life expectancy. Epigenetic clocks predict mortality more accurately than many traditional risk factors (Horvath & Raj, Nature Reviews Genetics, 2018).

The YEARS Evolve® program measures biological age using 7 different epigenetic clocks. This provides a unique insight into the aging process and allows for the objective measurement of the effectiveness of lifestyle interventions. For example, someone who optimizes their sleep, intensifies their exercise, or changes their diet can check months later to see if their biological age has actually changed. This concept is completely absent from the programs offered by Ezra and Prenuvo.

From Diagnostics to Longevity: The Role of Genomics and Research

The deepest insight into personal health architecture is offered by the YEARS Ultimate® program. The diagnostics are expanded by two crucial pillars:

1. Medical Genetics: A full sequencing of the exome and genome analyzes over 170 risk genes for cancer, cardiovascular, and metabolic diseases. A pharmacogenomic analysis reveals how the body responds to over 150 medications. This is the foundation for a radically personalized prevention strategy.
2. Microbiomics: The analysis of the gut microbiome provides insights into the interactions between diet, the immune system, and metabolic health.

More fundamental than the individual tests is the model behind them: the "Clinic-as-a-Study." Starting with the Evolve® program, 70 biological samples (blood, stool, urine, etc.) are cryopreserved for each patient in the "YEARS Biological Safe." Patients thus participate in a prospective longitudinal study. Anonymized data helps to better understand aging processes. At the same time, their own samples are available for future analyses as new scientific methods are developed.

In concrete terms, this means that someone who stores a sample today can benefit from a biomarker test in ten years that doesn't even exist yet. YEARS thus acts not just as a service provider, but as a scientific institution. Patients are not buying a one-time examination; they are investing in a long-term health and research platform.

Costs, Insurance, and Access: A Realistic Financial Breakdown

A direct price comparison is difficult because the services are fundamentally different. The costs reflect the diagnostic depth:

• Ezra: approx. $1,500 – $2,700
• Prenuvo: approx. $1,000 – $4,500
• YEARS:

* Core®: €1,900 (approx. $2,100) * Evolve®: €7,600 (approx. $8,300) * Ultimate®: €16,900 (approx. $18,500)

The Core® program already includes 87 biomarkers and extensive functional diagnostics that are missing from the US providers. Evolve® and Ultimate® can hardly be compared to Ezra or Prenuvo, as they represent a different category through the integration of full-body MRI, liquid biopsy, genomics, and biobanking.

For the German market, there is a tangible financial advantage: YEARS is a physician-led clinic and bills according to the German Medical Fee Schedule (GOÄ). This significantly increases the likelihood of reimbursement by private health insurance (PKV), as reimbursable medical indications are often identified during the comprehensive diagnostic process. This option is not available to German customers with the US providers.

The Medical Reality: Managing False Positives and Incidental Findings

In up to 95% of screened, asymptomatic individuals, abnormalities are found in full-body MRI scans (Weber et al., European Radiology, 2020). Around 91% of these findings are not clinically significant.

Nevertheless, such "incidentalomas" can lead to considerable anxiety, unnecessary follow-up tests, and sometimes invasive procedures with their own risks. A patient sent home with an unclear kidney finding after a screening MRI, who then waits weeks for a urology appointment, experiences this problem firsthand.

An imaging-only provider can leave you alone with an unclear finding. The YEARS approach structurally minimizes this problem: biomarkers, functional data, and genetics allow physicians to place an imaging finding in a much broader context. A small, unclear kidney finding in a patient with perfect kidney function values and unremarkable genetics is evaluated differently than in a patient with impaired kidney function and elevated hs-CRP.

The final, detailed strategy session with a YEARS physician transforms data into knowledge and knowledge into an actionable plan. Findings are medically contextualized and prioritized.

Conclusion: Which Full-Body Scan Is Right for You?

Choosing the right provider depends on your personal goals, your demand for medical depth, and your willingness to invest in long-term prevention.

Three distinct profiles emerge:

• For the time-crunched beginner: For those seeking a quick, imaging-only baseline and who are aware of its limitations, Ezra can be a reasonable starting point.
• For the image-focused individual: For those who prioritize high-resolution structural imaging and are willing to invest more for it, Prenuvo is a strong provider of MRI screening.
• For the data-driven strategist: For those who see health as an integrated system and want a deep, physician-led analysis of function, structure, molecular biology, and genetics, YEARS is the logical choice. It’s about knowing not just what is in your body, but why—and how to strategically manage it.

Prevention is more than just searching for anomalies. If you are ready for this comprehensive approach, the first step is a conversation.

Schedule a no-obligation consultation with the YEARS team to find out which approach is right for you.

Sources

1. Müller, H., Schmidt, P. (2022). 1.5T versus 3T in Whole-Body MRI: A Clinical Perspective on Signal, Artifacts, and Diagnostic Yield. Radiology Today.
2. Walldius, G., & Jungner, I. (2006). The apoB/apoA-I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy–a review of the evidence. Journal of internal medicine, 259(5), 493–519.
3. Schmidt, M., et al. (2023). Prevalence and Clinical Significance of Incidental Findings in Asymptomatic Individuals Undergoing Whole-Body MRI Screening. JAMA Oncology.
4. Parikh, A. R., et al. (2021). A multi-cancer early detection test in an asymptomatic screening population. Annals of Oncology, 32(S5), S1283-S1346.
5. Horvath, S., & Raj, K. (2018). DNA methylation-based biomarkers and the epigenetic clock theory of ageing. Nature Reviews Genetics, 19(6), 371–384.
6. Weber, M. A., et al. (2020). Incidental findings in whole-body magnetic resonance imaging. European Radiology, 30(5), 2649–2659.
7. Ridker, P. M., et al. (2008). Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein. New England Journal of Medicine, 359(21), 2195–2207.

This article is for general informational purposes only and does not constitute individual medical advice. The programs and their contents compared here are subject to change.